Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion

References

• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, Phase 3 trial. Lancet Oncol. 2017;18:1454–1466. doi:10.1016/S1470-2045(17)30608-3
   PubMed Web of Science ®Google Scholar
• Mok TS, Cheng Y, Zhou X, et al. Updated Overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. Drugs. 2021;81:257–266. doi:10.1007/s40265-020-01441-6
   PubMed Web of Science ®Google Scholar
• Harada G, Yang SR, Cocco E, et al. Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol. 2023;20:229–249. doi:10.1038/s41571-023-00733-6
   PubMed Web of Science ®Google Scholar
• Zhao Z, Su C, Xiu W, et al. Response to pralsetinib observed in meningeal-metastatic EGFR-Mutant NSCLC with acquired RET fusion: a brief report. JTO Clin Res Rep. 2022;3:100343. doi:10.1016/j.jtocrr.2022.100343
   PubMedGoogle Scholar
• Urbanska EM, Sørensen JB, Melchior LC, et al. Durable response to combined osimertinib and pralsetinib treatment for osimertinib resistance due to novel intergenic ANK3-RET Fusion in EGFR -mutated non–small-cell lung cancer. JCO Precis Oncol. 2022;6:e2200040. doi:10.1200/po.22.00040
   PubMed Web of Science ®Google Scholar
• Klempner SJ, Bazhenova LA, Braiteh FS, et al. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer. 2015;89:357–359. doi:10.1016/j.lungcan.2015.06.021
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4:1527–1534. doi:10.1001/jamaoncol.2018.2969
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to osimertinib in EGFR-Mutant NSCLC and clinical validation of combined EGFR and RET Inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529–1539. doi:10.1158/2159-8290.CD-18-1022
   PubMed Web of Science ®Google Scholar
• Vojnic M, Kubota D, Kurzatkowski C, et al. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. J Thorac Oncol. 2019;14:802–815. doi:10.1016/j.jtho.2018.12.038
   PubMed Web of Science ®Google Scholar
• Zhu VW, Klempner SJ, Ou SI. Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer. Trends Cancer. 2019;5:677–692. doi:10.1016/j.trecan.2019.09.008
   PubMed Web of Science ®Google Scholar
• Haura EB, Hicks JK, Boyle TA. Erdafitinib overcomes FGFR3-TACC3-mediated resistance to osimertinib. J Thorac Oncol. 2020;15:e154–e156. doi:10.1016/j.jtho.2019.12.132
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Oxnard GR, Cohen EF, et al. Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. Nat Commun. 2022;13:5614. doi:10.1038/s41467-022-33210-2
   PubMed Web of Science ®Google Scholar
• Osta BE, Ramalingam SS. RET fusion: joining the ranks of targetable molecular drivers in NSCLC. JTO Clin Res Rep. 2020;1:100050. doi:10.1016/j.jtocrr.2020.100050
   PubMedGoogle Scholar
• Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, Phase 2, single-arm trial. Lancet Oncol. 2016;17:1653–1660. 20161104. doi:10.1016/S1470-2045(16)30562-9
   PubMed Web of Science ®Google Scholar
• Ferrara R, Auger N, Auclin E, et al. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. J Thorac Oncol. 2018;13:27–45. doi:10.1016/j.jtho.2017.10.021
   PubMed Web of Science ®Google Scholar
• Yoh K, Seto T, Satouchi M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2017;5(1):42–50. doi:10.1016/S2213-2600(16)30322-8
   PubMed Web of Science ®Google Scholar
• Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–589. doi:10.1016/S1470-2045(16)30033-X
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28:270–277. doi:10.1093/annonc/mdw611
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378:113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50. doi:10.1056/NEJMoa1913662
   PubMed Web of Science ®Google Scholar
• Lavacchi D, Mazzoni F, Giaccone G. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. Drug Des Devel Ther. 2019;13:3187–3198. doi:10.2147/DDDT.S194231
   PubMed Web of Science ®Google Scholar
• Peng W, Pu X, Jiang M, et al. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: a brief report. Lung Cancer. 2021;152:66–70. doi:10.1016/j.lungcan.2020.12.008
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang Y, Liu Z, et al. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. Thorac Cancer. 2021;12:3407–3415. doi:10.1111/1759-7714.14222
   PubMed Web of Science ®Google Scholar
• Rotow J, Patel JD, Hanley MP, et al. Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers. Clin Cancer Res. 2023;29:2979–2987. doi:10.1158/1078-0432.CCR-22-2189
   PubMed Web of Science ®Google Scholar
• Zhang J, Ren Y, Wang Q, et al. Thoughts and suggestions on the fact that dacomitinib reduction did not affect its efficacy in the Archer 1050 study. Future Oncol. 2022;18:751–753. doi:10.2217/fon-2021-0983
   PubMed Web of Science ®Google Scholar
• Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023;389:1839–1850. doi:10.1056/NEJMoa2309457
   PubMed Web of Science ®Google Scholar
• Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry. 2004;75(2):ii43–50. doi:10.1136/jnnp.2004.040378
   PubMedGoogle Scholar
• Graus F, Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol. 2012;25:795–801. doi:10.1097/WCO.0b013e328359da15
   PubMed Web of Science ®Google Scholar
• Drilon A, Bergagnini I, Delasos L, et al. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann Oncol. 2016;27:1286–1291. doi:10.1093/annonc/mdw163
   PubMed Web of Science ®Google Scholar
• Shen T, Pu X, Wang L, et al. Association between RET fusions and efficacy of pemetrexed-based chemotherapy for patients with advanced NSCLC in China: a multicenter retrospective study. Clin Lung Cancer. 2020;21:e349–e354. doi:10.1016/j.cllc.2020.02.006
   PubMed Web of Science ®Google Scholar